- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. J Clin Oncol. 2022;40(10):1051-1058.
- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30(1):11-18.
- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: The randomized clinical FinXX trial. JAMA Oncol. 2017;3(6):793-800.
Perspectives
How does this study impact clinical practice?
- Patients with early breast cancer lived longer when adjuvant capecitabine was administered concomitantly with chemotherapy that included docetaxel and cyclophosphamide.
- The improvement in 15-year OS observed with addition of capecitabine to taxane-anthracycline adjuvant chemotherapy for early breast cancer patients was significant but modest (19%).
- Benefit was most apparent in patients with ER-negative cancer, HER2-negative cancer, and triple negative cancer, but subgroup analyses need to be interpreted with caution.
- This is the longest follow-up time reported for addition of capecitabine to neoadjuvant or adjuvant chemotherapy in breast cancer patients.
- Earlier analyses of data from the FinXX study at 5 years2 and 10 years3 did not report a significant OS benefit for capecitabine.
